The development of a national system for drug monitoring in Spain is described. The pharmaceutical market in many European countries is very different from that in other regions (eg, the Nordic Countries or the UK) with a tradition in drug surveillance activities. This paper focuses on the coordinated development of drug information and drug surveillance activities in a model country where a rational drug policy is urgently needed.
DukesG: The Effects of Drug Regulation.Lancaster, PA, MTP Press, 1985, pp 12–15.
2.
ErillS: Clinical pharmacology in Spain. Clin Pharmacol Ther1974; 16: 597–604.
3.
LaporteJRPortaMCapellàD: Drug utilization studies: A tool for determining the effectiveness of drug use. Br J clin Pharmac1983; 16: 301–304.
4.
ArnauJMLaporteJR: Fuentes de información sobre medicamentos utilizadas por médicos y farmacéuticos. Arch Farmacol Toxicol1983; 9: 109–114.
5.
ErillS: Información sobre medicamentos y su repercusión en la prescripción farmacológica, Avances en terapéutica.Barcelona, Salvat, 1981, vol 11, pp 18–28.
6.
TognoniG: A therapeutic formulary for Italian general practitioners. Lancet1978; 1: 1352–1353.
7.
AlvánGÖhmanBSjöqvistF: Problem-oriented drug information: A clinical pharmacology service. Lancet1983; 2: 1410–1412.
8.
LaporteJRTognoniG: Principios de epidemiología del medicamento.Barcelona, Salvat, 1983.
9.
Pan American Health Organization: Priority health needs in Central America and Panama.Washington, PAHO, 1984.
